Clinical trial NCT01882530: Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.
Official title: Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Post Operative Analgesia
Keywords: Post operative analgesia ;
Paracetamol ;
Ketoprofen ;
Nefopam ;
Morphine
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2013-06-20
Enrollment: 223
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia.

The objectives of this study are :

* comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.
* determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.
* evaluating the effects of NOA on postoperative hyperalgesia.

Detailed description: Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety?

Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds.

The objectives of this study are :

* comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.
* determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.
* evaluating the effects of NOA on postoperative hyperalgesia.

Eligibility criteria: Inclusion Criteria:

* Adults older than 18 years
* Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain
* Patients with a written informed consent
* Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned)
* Affiliate to a social security system

Exclusion Criteria:

* Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients
* Absorption of morphine and / or NOA within 24 hours before surgery
* Absorption of methadone within 48 hours before surgery
* History of epilepsy
* Renal insufficiency (creatinin clearance \<30 ml / min MDRD)
* Hepatic insufficiency
* Severe respiratory insufficiency
* Pregnancy or breastfeeding women
* History of seizures
* Symptomatic urethroprostatic disorders
* Angle-closure glaucoma
* Gastrointestinal, cerebrovascular or other evolving bleedings
* Active peptic ulcer or active gastritis
* Severe heart failure
* History of asthma triggered by taking ketoprofen or similar substances
* Disable adult person under guardianship
* Use of nitrous oxide during anesthesia protocol

Primary outcomes:
measure: Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).
timeFrame: Day 1
Secondary outcomes:
measure: Morphine consumption (mg) measured by patient controlled analgesia (PCA).
timeFrame: Day 2, day 3
measure: Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.
timeFrame: Day 3
measure: Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).
timeFrame: Day 2
measure: Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).
timeFrame: Month 3
measure: Global satisfaction (measured after treatment)
timeFrame: Day 3
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Karine Nouette-Gaulain
city: Boulogne
country: France
facility: Marcel Chauvin
city: Colombes
country: France
facility: Hawa Keita-Meyer
city: Garches
country: France
facility: Dominique Fletcher
city: Grenoble
country: France
facility: Pierre Albaladejo
city: Lyon
country: France
facility: Frédéric Aubrun
city: Montpellier
country: France
facility: Xavier Capdevila
city: Nancy
country: France
facility: Hervé Bouaziz
city: Nantes
country: France
facility: Karim Asehnoune
city: Nice
country: France
facility: Marc Raucoules
city: Nîmes
country: France
facility: Jacques Ripart
city: Paris
country: France
facility: Anissa Belbachir
city: Paris
country: France
facility: Emmanuel Marret
city: Paris
country: France
facility: Jean-Xavier Mazoit
city: Paris
country: France
facility: Marc Beaussier
city: Quincy sous Sénart
country: France
facility: Sébastien Bloc
city: Reims
country: France
facility: Jean-Marc Malinovsky
city: St Grégoire
country: France
facility: Marc Gentili
city: Toulouse
country: France
facility: Vincent Minville
Study officials:
affiliation: Rennes University Hospital
name: ERIC BELLISSANT
role: STUDY_CHAIR
References:
citation: Beloeil H, Albaladejo P, Sion A, Durand M, Martinez V, Lasocki S, Futier E, Verzili D, Minville V, Fessenmeyer C, Belbachir A, Aubrun F, Renault A, Bellissant E; OCTOPUS group. Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: the OCTOPUS study. Br J Anaesth. 2019 Jun;122(6):e98-e106. doi: 10.1016/j.bja.2018.10.058. Epub 2018 Dec 29.